BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and distribution in the U.S., of the 510(k) cleared automated calprotectin test, BÜHLMANN fCAL® turbo. The test, which aides in the diagnosis of inflammatory diseases in the gastrointestinal tract, will be distributed by Roche Diagnostics and used directly on the cobas® c501/502 chemistry analyzer systems in the US.
The direct application of the fCAL® turbo on the cobas® c501/502 analyzers will be a practical and fully automated testing procedure for modern core labs looking for fast and reliable results with little hands-on time. The combination of fCAL® turbo with the BÜHLMANN CALEX® Cap extraction device is a significant milestone marking freedom from the cumbersome and laborious manual methods of the past.
Newsletter Link: https://conta.cc/3t6mli9